Journal of PeriAnesthesia Nursing
Volume 24, Issue 5 , Pages 295-299 , October 2009

Interventional Procedures: Best Practice to Avoid Complications

  • Marcia Bixby, MS, RN, CNS-BC, CCRN

      Affiliations

    • Corresponding Author InformationAddress correspondence to Marcia Bixby, 145 North St, Randolph, MA 02368

References 

  1. Rudnick MR, Kesselheim A, Goldfarb S. Contrast-induced nephropathy: How it develops, how to prevent it. Cleveland Clin J Med. 2006;73:75–87
  2. Goldenberg I, Matetzky S. Nephropathy induced by contrast media: Pathogenesis, risk factors and preventive strategies. CMAJ. 2005;172:1461–1471
  3. Zirogiannis P, Rentoukas E, Lazaros G. Contrast media induced nephropathy in patients undergoing cardiac catherisation. Hellenic J Cardiol. 2004;45:107–113
  4. Ebert ME: Predicting and preventing contrast induced nephropathy. Imaging Econ, June 2006. Available at: http://www.imagingeconomics.com/issues/articles/2006-06_16. Accessed November 15, 2008.
  5. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: A clinical and evidence-based approach. Circulation. 2006;113:1799–1806
  6. Merten GJ, Burgess P, Lee G, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate. JAMA. 2004;291:2328–2334
  7. Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 hours of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. JACC. 2000;36:1542–1548
  8. Logar CM, Herzog CA, Beddhu S. Diagnosis and therapy of coronary artery disease in renal failure, end stage renal disease and renal transplant populations. Am J Med Sci. 2003;325:214–227
  9. Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in high risk patients undergoing angioplasty. N Engl J Med. 2003;348:491–499
  10. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105:2259–2264
  11. Palmers Y, DeGreef D, Grynne BH, et al. A double blind study comparing safety, tolerability and efficacy of iodixanol 320 mgI/ml and ioxaglate 320 mgI/ml in cerebral arteriography. Eur J Radiol. 1993;17:203–209
  12. Jo S, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between visipaque (Iodisanol) and Hexabris (Ioxaglate) in patients with renal insufficiency undergoing coronary angiography. JACC. 2006;48:924–930
  13. Davidson CJ, Laskey WK, Hermiller JB, et al. Randomized trial of contrast media utilization in high risk PTCA: The COURT trial. Circulation. 2000;101:2172–2177
  14. Heinrich MC, Kuhlmann MK, Grgic A, et al. Cytotoxic effects of ionic high osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro. Radiology. 2005;235:843–849
  15. Solomon R. Contrast media nephropathy—How to diagnose and how to prevent. Nephrol Dial Transplant. 2007;22:1812–1815
  16. Brigouri C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. JACC. 2002;40:298–393
  17. Pannu N, Wiebe N, Tonellli M. Prophylaxis strategies for contrast induced nephropathy. JAMA. 2006;295:2765–2769
  18. Gomes VO, Poli de Figueredo CE, Caramori P, et al. N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterization with an ionic low osmolality contrast medium: A multicentre clinical trial. Heart. 2005;91:774–778
  19. Marenzi G, Assanelli E, Marana I, et al. N-Acetylcysteine and contrast- induced nephropathy in primary angioplasty. N Engl J Med. 2006;354:2773–2782
  20. Brigouri C, Colombo A, Violante A, et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J. 2004;25:206–211
  21. Kshirsagar AV, Poole C, Mottl A, et al. N-Acetylcysteine for the prevention of radiocontrast induced nephropathy: A meta-analysis of prospective controlled trials. J Am Soc Nephrol. 2004;15:761–769
  22. Schmidt P, Pang D, Nykamp D, et al. N-Acetylcysteine and the sodium bicarbonate versus N-Acetylcysteine and standard hydration for the prevention of radiocontrast-induced nephropathy following coronary angiography. Ann Pharmacother. 2007;41:46–50
  23. Oldermeyer JB, Biddle WP, Wurdeman RL, et al. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J. 2003;146:1–6
  24. Bagshaw SM, Ghali W. Theophylline for prevention of contrast-induced nephropathy: A systematic review and meta-analysis. Arch Intern Med. 2005;165:1087–1093
  25. Spargias K, Alexopoulos E, Kyrzopoulos S, et al. Acsorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004;110:2837–2842
  26. Centers for Disease Control and Prevention. CDC Fact Sheet. Radiation emergencies. Department of Health and Human Services Centers for Disease Control and Prevention. 2005. Available at: http://www.bt.cdc.gov/radiation. Accessed November 1, 2008.
  27. Bryk SG, Censullo ML, Wagner LK, et al. Endovascular and interventional procedures in obese patients: A review of procedural technique modifications and radiation management. J Vasc Radiol. 2006;17:27–33
  28. Wagner LK: Radiation injury is a potentially serious complication to fluoroscopically guided complex interventions. Biomed Imaging Intervent J. Available at: http://www.biij.org/2007/2/e22. Accessed December 1, 2008.
  29. Koenig TR, Wolff D, Mettler FA, et al. Skin injuries from fluoroscopically guided procedures: Part 1: Characteristics of radiation injury. Am J Roentgenol. 2001;177:3–11
  30. Hirshfield JW, Balter S, Brinker JA, et al. ACCF/AHA/HRS/SCAI/clinical competence statement on physician knowledge to optimize patient safety and image quality in fluoroscopically guided invasive cardiovascular procedures. A report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training. JACC. 2004;44:2259–2282
  31. Miller DL, Balter S, Wagner LK, et al. Quality improvement guidelines for recording patient radiation dose in the medical record. J Vasc Intervent Radiol. 2004;15:423–429
  32. Shope TB. Radiation induced skin injuries from fluoroscopy. Radiographics. 1996;16:1195–1199
  33. Kuniak M, Azizova T, Day R, et al: The radiation injury severity classification system: An early injury assessment tool for the frontline health-care provider. 81:232–243, 2005
  34. Hon LQ, Ganeshan A, Thomas M, et al. Vascular closure devices: A comparative overview. Diagn Radiol. 2009;38:22–43
  35. Rashid M, Bailey S: Percutaneous femoral access and vascular closure devices. Available at: http://www.sis.org/docs/2007Yearbook_Ch1.pdf. Accessed November 15, 2008.
  36. Lins S, Guffy D, VanRiper S, et al. Decreasing vascular complications after percutaneous coronary interventions. Crit Care Nurs. 2006;26:38–45
  37. Hamner J, Dubois EJ, Riu T. Predictors of complications associated with closure devices after transfemoral percutaneous coronary procedures. Crit Care Nurs. 2005;25:30–37
  38. Shoulders-Odom B. Management of patients after percutaneous coronary interventions. Crit Care Nurs. 2008;28:26–40
  39. AccessClosure: Mynx information page. Available at: http://www.accessclosure.com/the mynx. Accessed November 8, 2008.
  40. St Jude Medical: Angio-Seal. Available at: http://www.sjmprofessional.com/EN-US/ProductLibrary/Pages/Angio-Seal-Vascular-Closure. Accessed December 8, 2008.
  41. Abbott Vascular: Mynx. Available at: http://www.accessclosure.com/the-mynx/procedure. Accessed December 8, 2008.

PII: S1089-9472(09)00319-0

doi: 10.1016/j.jopan.2009.07.002

Journal of PeriAnesthesia Nursing
Volume 24, Issue 5 , Pages 295-299 , October 2009

Article Tools